Zacks Downgrades Rhythm Pharmaceuticals to Strong Sell Amid Analyst Activity

Equities research firm Zacks Research recently downgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) from a “hold” rating to a “strong sell” rating. This decision was outlined in a research report issued to clients and investors on November 4, 2023. The downgrade comes amidst mixed reviews from various analysts, highlighting a fluctuating outlook for the biotechnology company.

On the same day as the downgrade, several other financial institutions released their assessments of Rhythm Pharmaceuticals. Notably, Needham & Company LLC raised its target price for the stock from $145.00 to $148.00, maintaining a “buy” rating. Similarly, UBS Group reiterated a “buy” rating, reflecting confidence in the company’s long-term potential. In contrast, Wall Street Zen lowered its rating from “hold” to “sell” just weeks prior, indicating a more cautious stance.

Analysts have provided a range of ratings for Rhythm Pharmaceuticals, with one analyst assigning a “strong buy,” fifteen giving a “buy,” one rating it as a “hold,” and two categorizing it as a “sell.” According to data from MarketBeat, the stock currently holds an average rating of “moderate buy” and a consensus price target of $131.29.

Recent Earnings and Financial Performance

Rhythm Pharmaceuticals announced its earnings results on November 4, 2023. The company reported a loss of ($0.82) earnings per share for the quarter, which fell short of analysts’ consensus estimates of ($0.72) by ($0.10). Despite this, the firm generated revenue of $51.30 million, surpassing the expected $50.71 million.

The company’s financial health continues to raise concerns, as evidenced by a negative return on equity of 433.21% and a net margin of 110.32%. Analysts forecast that Rhythm Pharmaceuticals will post an earnings per share of (4.32) for the current fiscal year.

Insider Transactions and Institutional Activity

Recent insider trading has also attracted attention. On October 30, 2023, insider Joseph Shulman sold 9,748 shares at an average price of $115.24, totaling approximately $1,123,359.52. This transaction reduced his holdings to 8,509 shares, valued at around $980,577.16. Similarly, insider Pamela J. Cramer sold 3,350 shares on December 11, 2023, at an average price of $111.00, amounting to $371,850.00. Following this sale, she retained 20,814 shares valued at $2,310,354.

In the last quarter, insiders collectively sold 15,913 shares of company stock, totaling $1,818,963. Corporate insiders now hold approximately 6.10% of the company’s stock, indicating a significant level of ownership.

Institutional investors have actively adjusted their positions in Rhythm Pharmaceuticals. Smartleaf Asset Management LLC increased its holdings by 97.2% during the third quarter, now owning 286 shares valued at around $29,000. Farther Finance Advisors LLC raised its holdings by an astounding 1,110.3%, acquiring 351 shares worth approximately $35,000. Other firms, including GAMMA Investing LLC and Osaic Holdings Inc., have also boosted their investments in the company, reflecting varied confidence in Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals, based in Boston, is a clinical-stage biotechnology firm specializing in therapies for rare genetic diseases related to obesity and metabolic dysfunction. The company focuses on the melanocortin-4 receptor (MC4R) pathway, which is crucial for regulating appetite and energy expenditure. Its lead product, setmelanotide, aims to restore normal weight regulation for patients with specific genetic deficiencies.

As analysts continue to scrutinize Rhythm Pharmaceuticals’ performance and outlook, the recent downgrades and insider activities underscore the dynamic nature of the biotechnology sector. Investors remain keenly interested in how the company will navigate future challenges and opportunities.